Sugarmade (SGMD) Numbers In Line with Cannabis Industry

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
406
Sugarmade (SGMD) Numbers In Line with Cannabis Industry Increasing Projections

- Projections for U.S. retail sales of medical, recreational cannabis on pace to reach $15 billion by end of 2020
- SGMD seeing consistent growth in numbers, supporting expert predictions
- CEO reports “increase in gross margins while demonstrating another breakout month-over-month performance on both the top and bottom line”

Even with the global COVID-19 pandemic causing a speed bump, projections for the retail sales of medical and recreational cannabis in the United states are on pace to reach $15 billion by the end of 2020 (https://nnw.fm/l4WzO). Those numbers, which are an increase of approximately 40% over 2019 sales figures, may not surprise Sugarmade (OTC: SGMD), which has consistently reported record numbers as it builds operations in the California cannabis space.

“Total U.S. sales could rise as high as $37 billion by 2024, according to exclusive projections from the latest Factbook, which was released Monday at MJBizConNEXT Direct,” reported a recent Marijuana Business Daily article. Despite the “huge curveball” that the coronavirus pandemic, threw at projections, the article went on to note that “spending on adult-use cannabis in markets that aren’t tourist-driven has increased, as have sales in nearly every domestic MMJ market.”

The report concluded that despite short-term uncertainty, the long-term potential of the cannabis industry remains intact. “Sharp sales increases in recently launched medical marijuana programs — as well as continued gains in adult-use markets — are expected to fuel much of the industry’s growth over the coming years.”

Recent financial reports from Sugarmade seem to confirm these projects. In its most recent numbers report, the company noted that gross sales for its BudCars Cannabis Delivery Service totaled $662,836, representing 32% month-over-month sales growth compared to June 2020 sales (https://nnw.fm/HuuOz). In addition, average daily gross sales increased 32% month-over month to $22,095, with total customer tickets increasing 33% month over month. In short, SGMD’s calendar Q3 is on pace to potentially more than double its calendar Q2 total BudCars sales.

“Last month featured strong growth in basically every major metric once again for our BudCars segment. We saw an increase in gross margins while demonstrating another breakout month-over-month performance on both the top and bottom line,” said Sugarmade CEO Jimmy Chan. “Note that April was our first full month operating BudCars. In July we more than doubled the sales and gross profits booked in April. That pace of growth suggests another potential doubling by October on a per-location basis. And we will be operating additional locations by then, which will serve to compound that growth.”

BudCars is a retail business that offers same-day delivery of top-quality cannabis. Customers choose from a variety of products including edibles, flower, pre-rolls, vapes, tinctures and concentrate across dozens of premium brands. Once consumers complete their purchases online, they receive their order the same day via BudCars Cannabis Delivery Service.

Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes CarryOutsupplies.com and SugarRush(TM).

For more information, visit the company’s website at www.Sugarmade.com.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Sugarmade Inc. (SGMD) Stock Research Links

SGMD Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading